Human Immunoglobulin E specific for Artemisia annua pollen allergens (IgE (Artemisia annua))

Human Immunoglobulin E (IgE) specific for Artemisia annua pollen allergens is a specialized class of antibodies that mediates Type I hypersensitivity reactions to sweet wormwood pollen. These antibodies are produced following sensitization to major allergens such as Art a 1, a defensin-like protein, and Art a 2, which are highly prevalent in regions like East Asia (WHO/IUIS Allergen Nomenclature). Once formed, these IgE molecules bind to high-affinity receptors (FcεRI) on the surface of mast cells and basophils. Upon subsequent exposure to the pollen, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine and leukotrienes (StatPearls, Type I Hypersensitivity). This physiological response leads to the clinical manifestation of allergic rhinitis, conjunctivitis, and seasonal asthma. These specific IgE antibodies are the primary target of allergen-specific immunotherapy (AIT), which seeks to induce immunological tolerance, and are also sequestered by anti-IgE biologics such as Omalizumab (NCBI, PubChem). Monitoring serum levels of these antibodies is a standard diagnostic procedure for identifying specific pollen sensitivities in allergic patients.

Other names

Anti-Artemisia annua IgESweet wormwood pollen-specific IgEArt a 1-specific IgEArtemisia annua-specific IgE

Anti-IgE monoclonal antibodies bind to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (PubMed, PMID: 24565708). Allergen-specific immunotherapy (AIT) interacts with these antibodies by inducing immune tolerance and promoting the production of competing IgG4 antibodies (Journal of Allergy and Clinical Immunology).